# Novartis operational restructuring and market volatility > Live situation record from CLSTR: https://clstr.news/situations/novartis-operational-restructuring-and-market-volatility > Updated: 2026-09-10T09:13:53.000Z. Sources: 4. Developments: 2. Novartis has undergone significant operational and financial shifts. Initially, the company announced a strategic restructuring in Basel, Switzerland, involving the cutting of approximately 130 jobs. This plan includes phasing out small-volume biologics production at the Kleinbasel site by the end of 2027 and relocating technical development, analytical testing, and biological cell bank laboratories to the main Novartis campus by the end of 2028. Following these restructuring efforts, the company faced a major market setback. Novartis’s stock price dropped by more than 10 percent in a single day, causing a loss of roughly 24 billion Swiss francs in market value and impacting the Swiss Market Index. This decline was driven by clinical research failures, specifically regarding the drugs Pelacarsen for cardiovascular diseases and Del-Desiran for a genetic muscle disease. These setbacks have led to scrutiny over the company’s 12-billion-dollar acquisition of Avidity Biosciences. ## Timeline ### 2026-09-10: Novartis faces market decline following clinical research setbacks Novartis shares plummeted over 10 percent, erasing 24 billion CHF in market value following multiple clinical trial failures in its pharmaceutical pipeline. 2 sources. https://clstr.news/cluster/novartis-faces-market-decline-following-clinical-research-setbacks ### 2026-09-03: Novartis to cut 130 Swiss jobs and relocate biologics labs Novartis will cut approximately 130 jobs in Switzerland and phase out small-scale biologics production in Kleinbasel by 2027 to consolidate operations at its main Basel campus. 2 sources. https://clstr.news/cluster/novartis-to-cut-130-swiss-jobs-and-relocate-biologics-labs --- Cite as: Novartis operational restructuring and market volatility. CLSTR, https://clstr.news/situations/novartis-operational-restructuring-and-market-volatility